Introduction
============

The clinical course of relapsing-remitting multiple sclerosis (RRMS) is highly heterogeneous and prognostic biomarkers at time of diagnosis are lacking. Early identification of patients at risk of an unfavorable mid- to long-term outcome is critical, as this knowledge may help select the most appropriate therapeutic strategy and provide adequate counseling. Converging evidence support the hypothesis that auto reactive T-cells primed outside the central nervous system (CNS) are key to the pathogenesis of MS ([@B13]; [@B10]). We hypothesized that the blood proteome is modified by early pathological processes, and is a source of prognostic biomarkers at time of diagnosis. Several studies have used (immuno)proteomics tools to analyze the blood proteome in MS, with the aim of identifying diagnostic biomarkers and dysregulated pathways which may shed light on the pathogenenic intricacies of MS ([@B1]; [@B2]; [@B15]; [@B18]; [@B11]; [@B3]; [@B4]; [@B9]; [@B21]). However, none of these studies have related the proteomic changes to long term outcomes. Here, we investigated whether a protein expression signature was associated with clinical, cognitive or MRI outcomes, 11 years after diagnosis in a cohort of 67 well characterized RRMS patients. Biobanked plasma was interrogated using a novel aptamer-based multiplexed proteomic platform, which allows to measure levels of 1310 predetermined proteins including cell signaling molecules, receptors and proteins involved in neuronal repair ([@B8]).

Methods
=======

Patients
--------

This study was performed according to the ethical principles of the Declaration of Helsinki and was approved by the local ethics committee (VUmc, Amsterdam, Netherlands). All patients signed informed consent for the use of plasma and clinical information. Patients were recruited on a voluntary basis at the MS center of the VU University Medical Center, Amsterdam, Netherlands. At year 11, patients fulfilled the 2001 revisions of the McDonald criteria for RRMS ([@B12]). During follow-up, disease modifying therapies (DMTs) were introduced by the treating neurologist in 47.8% of patients. Of these, 68.7% received first line therapies only, while 33.1% subsequently received second line DMTs. No healthy controls were included in this study, as the aim was to explore the predictive value of the plasma proteome in RRMS patients.

Plasma
------

Plasma was collected within 3 months of diagnosis, but at least 6 weeks from a relapse (referred to as baseline), and processed and stored according to international state-of-the-art guidelines on biobanking ([@B20]).

Clinical and Cognitive Measures
-------------------------------

Expanded disability status scores (EDSS) were determined by certified clinicians at baseline and year 11 for the whole cohort (*n* = 67), and ΔEDSS was calculated. Cognitive performance in seven different cognitive domains was determined at year 11 for 49 patients. Cognitive test scores were transformed into domain-specific Z-scores, based on a matched healthy control group (*n* = 29), and a global cognitive score was calculated as published ([@B6]).

MRI Measures
------------

MRI was acquired at year 11 for 46 patients using a General Electric 3 Tesla MRI system with an 8-channel head coil. Normalized whole brain volume and normalized thalamic volume were measured on 3-dimensional T1-weighted images using SIENAX and FIRST \[both part of FSL ([@B16])\] and transformed into Z-scores, based on volumes in a matched healthy control group (*n* = 59), as done previously ([@B5]). White matter lesion volume was calculated on fluid-attenuated inversion recovery images using an automated segmentation technique ([@B17]).

Plasma Proteomics
-----------------

The proteome of each plasma sample was assessed using the SOMAscan (SomaLogic, Boulder, CO, United States), a multiplexed proteomic platform using protein-capture SOMAmers (Slow Off-rate Modified Aptamers) to measure the levels of a predefined set of 1310 proteins ([@B8]). Aptamers are single stranded DNA molecules that are modified to mimic protein side chains, which allow selective binding to protein targets of interest. Moreover, theses DNA aptamers are able to pair with DNA probes, allowing quantification using a DNA microarray. Therefore, the measurement output is in relative fluorescence units (RFU). The reported intra and inter-run coefficient of variation (CV%) in blood are \<5% ([@B8]). Two levels of quality controls were performed; (1) to avoid relative signal variation between the samples at the microarray level, a set of aptamers with the lowest overall signal variation was used for normalization within plates, (2) the median RFU for a set of aptamer used for normalization was calculated from all the samples and a scaling factor for each individual sample was calculated to control for the technical variability.

Outcome Measures
----------------

Four dichotomic outcome measures were defined: (i) EDSS outcome; EDSS progression was defined as a ΔEDSS ≥ 1; (ii) cognitive impairment; impaired cognition was defined as a cognitive score of Z \< −2 in two or more cognitive domains compared to healthy controls; (iii) whole brain volume outcome; whole brain atrophy was defined as a normalized brain volume Z \< −2 compared to healthy controls; (iv) thalamic volume outcome; thalamic atrophy was defined as normalized thalamic volume Z \< −2 compared to healthy controls. A fifth, continuous outcome, consisted of white matter lesion volume at year 11.

Statistical Analysis
--------------------

Statistical analysis was performed is SPSS (version 20.0.0.0) and R (version 3.2.3). Proportions for categorical variables and mean values for continuous variables were compared using chi-square, student's *t*-test and the Mann--Whitney test. Differentially expressed proteins were identified using the Limma-package in R, which implements a moderated *t*-test followed by the FDR (False Discovery Rate) multiplicity correction. Predictive power was assessed by the global test ([@B7]) and penalized regression. A generalized linear regression model linking the outcome to the protein data was fitted in penalized -lasso, ridge and elastic net- fashion by means of the "glmnet" R-package. Performance of the thus built predictor was evaluated on left-out samples in the outer loop, with penalty parameter(s) determined through cross-validation in an inner loop.

Results
=======

Demographic, clinical and MRI characteristics of the RRMS cohort are presented in Table [1](#T1){ref-type="table"}. The cohort was dichotomized into outcome groups, according to the aforementioned four categorical outcome measures. ΔEDSS, cognitive scores, whole brain volume and thalamic volume were significantly different between outcome groups of the respective categorical outcome measure (Table [2](#T2){ref-type="table"}). Mean age and the proportion of females did not differ between outcome groups for all four outcome measures (Table [2](#T2){ref-type="table"}). The proportion of DMT-treated individuals did not differ between outcome groups for the EDSS, cognitive impairment and whole brain volume outcome measures (Table [2](#T2){ref-type="table"}). For the thalamic volume outcome measure, the proportion of DMT-treated individuals was higher in those with thalamic atrophy at year 11 compared to those without (Table [2](#T2){ref-type="table"}, *p* = 0.02). We could reliably measure 1310 proteins in all the plasma samples of the cohort, and the mean units per protein are presented in Supplementary Data Sheet [S1](#SM1){ref-type="supplementary-material"}. When we compared the global plasma protein expression profile at baseline between outcome groups for all four categorical outcome measures, we found no difference between individuals with or without EDSS progression (*p* = 0.651), with or without cognitive impairment (*p* = 0.802), with or without whole brain atrophy (*p* = 0.094), or with or without thalamic atrophy (*p* = 0.491). Moreover, we found no significant association between the proteomic profile and white matter lesion volume at year 11 (*p* = 0.111). Next, we assessed the classification performance of the proteomic features at baseline for three of the categorical outcomes, and found that no classifier could differentiate EDSS progression, cognitive impairment, or thalamic atrophy at 11-year (Figure [1](#F1){ref-type="fig"}). Because of the small number of individuals with whole brain atrophy at year 11 (*n* = 10), a classifier could not be built for this outcome measure.

###### 

Clinical and radiological characteristics of the cohort of relapsing remitting multiple sclerosis patients (*n* = 67).

                 **Mean age in years (SD)**   **Median EDSS (range)**   **Mean total brain volume Z-score compared to healthy controls (range)**   **Mean thalamic volume Z-score compared to healthy controls (range)**   **Mean global cognitive score Z-score compared to healthy controls (range)**   **% female**   **% DMT (% escalation)**
  -------------- ---------------------------- ------------------------- -------------------------------------------------------------------------- ----------------------------------------------------------------------- ------------------------------------------------------------------------------ -------------- --------------------------
  **Baseline**   32.7 (9.5)                   2.0 (0 to 4.5)            NA                                                                         NA                                                                      NA                                                                             68.7           0
  **Year 11**    43.7 (9.5)                   3.0 (1.0--6.5)            −0.9 (−5.1 to 0.8)                                                         −2.1 (−8.0 to −1.0)                                                     −0.7 (−2.0 to 0.7)                                                             68.7           47.8 (31.3)

###### 

Number of individuals and clinical characteristics according to clinical cognitive or MRI outcome measures; EDSS scores were available at baseline and year 11 for all individuals (*n* = 67).

  **Outcome measure i**                                        ***N***   **Median EDSS at baseline (range)**                                                **Median EDSS at y 11 (range)**                                                        **Mean age at baseline (SD) in years**   **% Female**   **% DMT (% escalation)**
  ---------------------------- ------------------------------- --------- ---------------------------------------------------------------------------------- -------------------------------------------------------------------------------------- ---------------------------------------- -------------- --------------------------
  EDSS                         EDSS progression at y11         38        1.8 (0 to 4.0)                                                                     3.0 (1.0 to 6.5)                                                                       32.6 (10.3)                              68.4           39.5 (10.5)
                               No EDSS progression at y11      29        2.0 (1.0 to 4.5)                                                                   2.5 (1.0 to 4.0)                                                                       32.9 (8.5)                               69.0           58.6 (20.7)
                               *p*-value                       .         *p* = 0.03                                                                         *p* \< 0.001                                                                           *p* = 0.89                               *p* = 0.96     *p* = 0.12 (*p* = 0.26)
  **Outcome measure ii**                                       ***N***   **Mean global cognitive score Z-score compared to healthy controls at baseline**   **Mean global cognitive score Z-score compared to healthy controls at y 11 (range)**   **Mean age at baseline (SD) in years**   **% Female**   **% DMT (% escalation)**
  Global cognitive scale       Impaired cognition at y11       14        NA                                                                                 −1.4 (−2.0 to −0.9)                                                                    34.1 (11.3)                              57.1           50.0 (7.1)
                               No impaired cognition at y11    35        NA                                                                                 −0.5 (−1.4 to 0.7)                                                                     33.6 (7.5)                               82.9           51.4 (17.1)
                               *p*−value                       .         NA                                                                                 *p* \< 0.001                                                                           *p* = 0.69                               *p* = 0.21     *p* = 0.93 (*p* = 0.64)
  **Outcome measure iii**                                      ***N***   **Mean total brain volume Z-score compared to healthy controls at baseline**       **Mean total brain volume Z-score compared to healthy controls at y 11 (range)**       **Mean age at baseline (SD) in years**   **% Female**   **% DMT (% escalation)**
  Total brain volume           Total brain atrophy at y11      6         NA                                                                                 −3.2 (−5.1 to −2.2)                                                                    29.3 (8.0)                               83.3           83.3 (50.0)
                               No total brain atrophy at y11   40        NA                                                                                 −0.5 (−2.0 to 0.8)                                                                     33.8 (8.5)                               75.0           47.5 (10.0)
                               *p*-value                       .         NA                                                                                 *p* \< 0.001                                                                           *p* = 0.22                               *p* = 0.66     *p* = 0.10 (*p* = 0.03)
  **Outcome measure iv**                                       ***N***   **Mean thalamic volume Z-score compared to healthy controls at baseline**          **Mean thalamic volume Z-score compared to healthy controls at y 11 (range)**          **Mean age at baseline (SD) in years**   **% Female**   **% DMT (% escalation)**
  Thalamic volume              Thalamic atrophy at y 11        21        NA                                                                                 −3.6 (−8.0 to −2.0)                                                                    31.8 (8.6)                               76.2           71.4 (23.8)
                               No thalamic atrophy at y 11     25        NA                                                                                 −0.9 (−2.0 to 1.0)                                                                     34.5 (8.3)                               76.0           36.0 (8.0)
                               *p*-value                       .         NA                                                                                 *p* \< 0.001                                                                           *p* = 0.97                               *p* = 0.99     *p* = 0.02 (*p* = 0.05)
  **Outcome measure v**                                        ***N***   **Mean T2 volume at baseline**                                                     **Mean T2 volume at y 11 in mm^3^ (range)**                                            **Mean age at baseline (SD) in years**   **% Female**   **% DMT (% escalation)**
  White matter lesion volume                                   46        NA                                                                                 13626.2 (3525.3 to 51882.7)                                                            33.2 (8.5)                               76.1           52.2 (15.2)

Cognition scores and MRI parameters were available for n = 49 and n = 46 individuals respectively; p-values are provided for the comparison of each outcome parameter between outcome group. HC, healthy controls; EDSS, extended disability status scores; SD, standard deviation; DMT, disease modifying therapy; NA, not available; n, number; y11, year 11 follow-up; % escalation indicates individuals which received second line DMTs.

![Receiver operating characteristic (ROC) curve showing the predictive performance of baseline proteome for **(A)** EDSS outcome measure, **(B)** global cognitive score measure, and **(C)** thalamic volume measure. Three curves are represented, acquired using 3 types of linear regression models to link the proteomic data to the outcomes. EDSS, expanded disability status score; AUC, area under the curve.](fnmol-11-00371-g001){#F1}

Discussion
==========

We interrogated the plasma proteome at diagnosis in 67 well characterized RRMS patients, and found no signature associated with dichotomized clinical, cognitive or MRI outcomes, or with white matter lesion volume 11 years after diagnosis. We used an innovative proteomics technology which allowed us to measure a predefined panel of 1310 proteins in plasma, including low abundant proteins. A subset of the proteins of the SOMAscan are of known relevance to MS, such as brain-derived neurotrophic factor, Chitinase-3-like protein 1 (aka YKL-40), hepatocyte growth factor, Contactin-2, and osteopontin ([@B19]). In addition, the panel includes proteins involved in inflammation and immune responses, and in CNS repair. Our cohort is representative of the demographics of MS in the general population, with female overrepresentation and mean age at disease onset in the early thirties. The proportion of individuals with whole brain atrophy was low, because we used a stringent definition of atrophy in order to retain high specificity. The proportion of DMT-treated individuals did not differ between outcome groups for the EDSS and cognitive function outcome measures, but was higher in individuals with thalamic atrophy compared to the group without. This finding may reflect the higher incentive to treat individuals with paraclinical signs for a more severe disease course, such as early thalamic atrophy. Several limitations may explain our results. First, our cohort consisted of individuals with a relatively mild disease course, and the differences in outcome measures between the dichotomised groups, although significant, were modest. Although this cohort may reflect the disease course of a majority of RRMS patients, a cohort with more dramatic differences in outcomes, if available, may be better suited for the exploratory nature of the study. Second, the size of the cohort was relatively small, yet larger than most of the MS cohorts investigated by proteomics and reported in the literature so far ([@B1]; [@B2]; [@B15]; [@B3]; [@B9]; [@B21]). Third, 47.8% of patients were treated with DMTs, which may modulate disease course. However, the proportion of DMT-treated individuals did not differ between outcome groups for the EDSS, global cognitive scale and whole brain volume outcome measures, indicating DMTs may not be a main determinant of outcome, 11 years after diagnosis in this cohort for these measures. Forth, the panel of proteins measured in plasma may in fact not have prognostic potential. However, in contrast to unbiased proteomic tools, this platform allows to measure low abundant proteins, including signaling molecules and brain-derived proteins, which could have reflected disease activity. Fifth, plasma storage time was long (12 years), and although the samples were collected within a few months of each other, processed identically, and stored according to international state-of-the-art guidelines on biobanking, storage time may have affected protein levels. Few studies have investigated the effect of long term storage on the plasma proteome. A mass spectrometry study found no difference in the number and intensity of peaks between plasma samples collected 4 years apart ([@B14]). The effect of longer storage times on the plasma proteome has not been investigated so far, but as storage time was the same for all samples, we do not expect a large influence on the results of this study. Sixth, plasma may not be a source for the discovery of early prognostic biomarkers. Indeed, the influence of peripheral organs on the blood proteome is high, and in this respect, cerebrospinal fluid may be better suited for biomarker discovery. Finally, disease prognosis may be difficult to predict at time of first clinical signs of disease, as many factors, amongst which infectious diseases, vitamin D levels, diet and lifestyle, may modulate disease course.
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